Knowing What Not to Build

Strategy is one of the most frequently used and least understood words in business.

In biotechnology, we often mistake scientific ambition for strategy.

We describe a broad pipeline as a strategy.

We describe becoming "the leader in AI" as a strategy.

We describe entering multiple therapeutic areas as a strategy.

These are aspirations.

Strategy is something different.

Michael Porter famously argued that competitive advantage comes from making deliberate choices. Strategy is not about doing everything well. It is about deciding what not to do. Sustainable advantage comes from creating a position that competitors cannot easily replicate.

Clayton Christensen added another dimension.

His theory of disruptive innovation explained why market leaders often fail, not because they stop innovating, but because they become exceptionally good at serving today's customers while overlooking tomorrow's markets.

Together, Porter and Christensen transformed how executives think about business.

Yet biotechnology has always behaved differently from most industries.

Today, artificial intelligence, platform technologies, and precision medicine are exposing where those classic theories require refinement.

Healthcare Doesn't Behave Like Most Markets

Christensen's model was built around disruption entering from the low end of a market.

Personal computers challenged mainframes.

Mini mills challenged integrated steel producers.

Digital photography displaced film.

Streaming replaced DVDs.

Healthcare rarely follows that pattern.

Patients rarely choose the lowest-cost therapy.

Physicians prioritize clinical evidence over convenience.

Regulators demand years of validation.

Payers introduce entirely different economic incentives.

The result is that many disruptive healthcare technologies do not begin as inferior products.

They begin as scientifically uncertain ones.

Gene therapy.

CAR-T.

RNA therapeutics.

Artificial intelligence.

Each initially appeared expensive, specialized, and difficult to implement.

Yet each addressed problems that conventional technologies simply could not solve.

Disruption in biotechnology often enters from the frontier of science rather than the bottom of the market.

Platform Technologies Don't Follow Traditional Rules

Porter emphasized unique positioning.

Christensen emphasized market disruption.

Modern biotechnology increasingly revolves around something else.

Platforms.

Artificial intelligence platforms.

Antibody discovery platforms.

Gene editing platforms.

Cell engineering platforms.

Spatial biology platforms.

These technologies become more valuable every time they are used.

Every experiment generates new data.

Every partnership improves the platform.

Every customer expands the knowledge base.

Competitive advantage is no longer defined solely by products.

It is increasingly defined by learning.

The organizations that learn fastest create the strongest platforms.

External Innovation Has Become Strategy

Perhaps the greatest change over the past two decades is that no organization can realistically innovate alone.

The scientific landscape has become too broad.

Academic laboratories generate foundational biology.

Biotechnology companies develop specialized platforms.

Artificial intelligence companies build computational capabilities.

Large pharmaceutical companies contribute development expertise, manufacturing infrastructure, regulatory experience, and commercial scale.

Strategy is no longer simply deciding what your organization will build.

It is deciding what your organization should never attempt to build internally.

That distinction has profound implications.

External innovation is no longer just business development.

It has become corporate strategy.

AI Changes the Nature of Competitive Advantage

Artificial intelligence introduces another important revision to traditional strategy.

Historically, products created value.

Today, learning systems create value.

An AI platform improves with every experiment.

A foundation model becomes more capable as additional biological knowledge is incorporated.

Discovery engines continuously refine future predictions.

This creates feedback loops that Porter and Christensen could not fully anticipate.

Competitive advantage increasingly comes from owning the system that learns, not simply the product that is sold.

A Revised Theory for Biotechnology

If Porter taught us that strategy requires difficult choices, and Christensen taught us that incumbents often overlook emerging technologies, today's biotechnology leaders face a third challenge.

They must build organizations capable of continuously learning from technologies they do not entirely own.

That requires a different strategic framework.

Protect core capabilities.

Partner aggressively.

Invest in platforms rather than isolated products.

Treat artificial intelligence as an enabling layer rather than another software application.

Build ecosystems instead of pipelines.

Measure learning as carefully as revenue.

Most importantly, recognize that tomorrow's competitive advantage may come from integrating technologies more effectively than inventing every one of them.

Looking Ahead

The next decade of biotechnology will not be defined by companies with the largest R&D budgets.

Nor by those pursuing the broadest pipelines.

It will belong to organizations that make disciplined strategic choices while remaining open to scientific innovation wherever it emerges.

The winners will know what to build.

What to partner.

What to license.

What to acquire.

And perhaps most importantly, what not to pursue.

Strategy has always been about making choices.

In biotechnology, those choices are becoming less about products and more about platforms, partnerships, and learning.

That may be the most important evolution of strategy since Porter first asked a deceptively simple question:

What is strategy?